Sulfuretin isolated from heartwood of Rhus verniciflua inhibits LPS-induced inducible nitric oxide synthase, cyclooxygenase-2, and pro-inflammatory cytokines expression via the down-regulation of NF-κB in RAW 264.7 murine macrophage cells

被引:77
作者
Shin, Ji-Sun [1 ]
Park, Young Mi [1 ]
Choi, Jung-Hye [2 ]
Park, Hee-Juhn [3 ]
Shin, Min Cheol [4 ]
Lee, Yong Sup [4 ]
Lee, Kyung-Tae [1 ]
机构
[1] Kyung Hee Univ, Dept Pharmaceut Biochem, Coll Pharm, Seoul 130701, South Korea
[2] Kyung Hee Univ, Dept Oriental Pharmaceut Sci, Coll Pharm, Seoul 130701, South Korea
[3] Sangji Univ, Dept Pharmaceut Engn, Wonju, South Korea
[4] Kyung Hee Univ, Dept Life & Nanopharmaceut Sci, Coll Pharm, Seoul 130701, South Korea
关键词
Sulfuretin; Nitric oxide synthase; Cyclooxygenase-2; Cytokines; Nuclear factor-kappa B; GENE-EXPRESSION; STOKES; KINASE; IDENTIFICATION; FLAVONOIDS; PATHWAY; INNATE; INTERLEUKIN-6; SUPPRESSION; APOPTOSIS;
D O I
10.1016/j.intimp.2010.05.007
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
It has been reported that Rhus verniciflua exhibits anti-inflammatory, anti-oxidant and anti-cancer activities. However, little is known about biological activity of sulfuretin, a flavonoid isolated from R. verniciflua. In the present study, we investigated the anti-inflammatory effect and the underlying molecular mechanisms of sulfuretin in lipopolysaccharide (LPS)-induced RAW 264.7 cells. Sulfuretin dose-dependently reduced the productions of nitric oxide (NO), prostaglandin E-2 (PGE(2)), tumor necrosis factor-alpha (TNF-alpha), and interleukin-1 beta (IL-1 beta) induced by LPS. Consistent with these findings, sulfuretin significantly suppressed the LPS-induced expressions of inducible nitric oxide synthase (iNOS), cyclooxygenase-2 (COX-2), TNF-alpha, and IL-1 beta. In addition, sulfuretin attenuated LPS-induced DNA binding and the transcriptional activities of nuclear factor-kappa B (NF-kappa B), which was accompanied by a parallel reduction of degradation and phosphorylation of inhibitory kappa B-alpha (I kappa B-alpha) and consequently by decreased nuclear translocation of p65 subunit of NF-kappa B. Furthermore, pretreatment with sulfuretin significantly inhibited the LPS-stimulated activation of I kappa B kinase beta (IKK beta). Taken together, these results suggest that the anti-inflammatory effect of sulfuretin in LPS-treated RAW 264.7 macrophages is associated with the suppression of NF-kappa B transcriptional activity via the inhibitory regulation of IKK beta phosphorylation. (C) 2010 Elsevier B.V. All rights reserved.
引用
收藏
页码:943 / 950
页数:8
相关论文
共 52 条
[2]   The two NF-κB activation pathways and their role in innate and adaptive immunity [J].
Bonizzi, G ;
Karin, M .
TRENDS IN IMMUNOLOGY, 2004, 25 (06) :280-288
[3]  
Choi J, 2003, PLANTA MED, V69, P899, DOI 10.1055/s-2003-45097
[4]   p38 MAPK and NF-κB collaborate to induce interleukin-6 gene expression and release -: Evidence for a cytoprotective autocrine signaling pathway in a cardiac myocyte model system [J].
Craig, R ;
Larkin, A ;
Mingo, AM ;
Thuerauf, DJ ;
Andrews, C ;
McDonough, PM ;
Glembotski, CC .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2000, 275 (31) :23814-23824
[5]   PROSTAGLANDIN-G/H SYNTHASE ISOENZYME-2 EXPRESSION IN FIBROBLASTS - REGULATION BY DEXAMETHASONE, MITOGENS, AND ONCOGENES [J].
EVETT, GE ;
XIE, WL ;
CHIPMAN, JG ;
ROBERTSON, DL ;
SIMMONS, DL .
ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS, 1993, 306 (01) :169-177
[6]   Missing pieces in the NF-κB puzzle [J].
Ghosh, S ;
Karin, M .
CELL, 2002, 109 :S81-S96
[7]  
Guzik TJ, 2003, J PHYSIOL PHARMACOL, V54, P469
[8]   NF-κB and the innate immune response [J].
Hatada, EN ;
Krappmann, D ;
Scheidereit, C .
CURRENT OPINION IN IMMUNOLOGY, 2000, 12 (01) :52-58
[9]   Discovery and analysis of inflammatory disease-related genes using cDNA microarrays [J].
Heller, RA ;
Schena, M ;
Chai, A ;
Shalon, D ;
Bedilion, T ;
Gilmore, J ;
Woolley, DE ;
Davis, RW .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1997, 94 (06) :2150-2155
[10]   Cyclooxygenase-2 - 10 years later [J].
Hinz, B ;
Brune, K .
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2002, 300 (02) :367-375